Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
A squamous cell carcinoma that arises from the tongue. It usually presents as a painful ulcerated or nodular lesion. The size of the tumor and the status of the lymph nodes are the most important factors that determine prognosis.
Biomarker and diagnostic research for tongue squamous cell carcinoma has been reported in the published literature.
8 clinical trials registered, 3 recruiting. Interventions under study include procedural interventions, other interventions, and drug therapy. Pipeline includes 4 PHASE2, 1 PHASE1, 3 NA. Research is sponsored by a mix of industry and academic institutions.
NCT ID | Title | Phase | Sponsor | Status |
|---|---|---|---|---|
[NCT07217171](https://clinicaltrials.gov/study/NCT07217171) |
Data assembled from 3 of 12 sources · Last updated Sep 18, 2026, 11:19 PM UTC
A Study Evaluating the Safety, Efficacy, and Pharmacokinetics (PK) of EVOLVE104 in Participants With Advanced Urothelial and Squamous Cell Carcinomas |
PHASE1 |
EvolveImmune United, Inc |
RECRUITING |
[NCT06450080](https://clinicaltrials.gov/study/NCT06450080) | Study of the Relationship Between Clinical, Imaging and Biological Data in Patients With Squamous Cell Carcinoma of the Tongue | NA | Centre Hospitalier Universitaire, Amiens | UNKNOWN |
[NCT07346807](https://clinicaltrials.gov/study/NCT07346807) | Lingual Nerve Disruption to Augment Neoadjuvant Chemoimmunotherapy in Locally Advanced Tongue Cancer | PHASE2 | Shanghai Zhongshan Hospital | UNKNOWN |
[NCT03799445](https://clinicaltrials.gov/study/NCT03799445) | Ipilimumab, Nivolumab, and Radiation Therapy in Treating Patients With HPV Positive Advanced Oropharyngeal Squamous Cell Carcinoma | PHASE2 | M.D. Anderson Cancer Center | UNKNOWN |
[NCT07466810](https://clinicaltrials.gov/study/NCT07466810) | Resection and Defect Repair of Oral Cancer Aided by Mixed Reality Technology | NA | Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University | UNKNOWN |
247 publications have been identified in PubMed for tongue squamous cell carcinoma. Kisho has analyzed 193 by research type. Research spans Basic Science / Preclinical (35%), Diagnostic / Biomarker (24%), and Epidemiology / Natural History (12%).
Research Type | Count | % of Total |
|---|---|---|
Laboratory research | 67 | 35% |
Testing and diagnosis research | 47 | 24% |
Disease patterns and progression | 24 | 12% |
New treatment approaches | 24 | 12% |
Research summaries | 10 | 5% |
Patient case studies | 9 | 5% |
Clinical study results | 9 | 5% |
Other research | 3 | 2% |
Hijioka H (2026). [PMID: 41544048](https://pubmed.ncbi.nlm.nih.gov/41544048/). *PLoS One*. [Diagnostic / Biomarker]
Koivuholma A (2026). [PMID: 40908723](https://pubmed.ncbi.nlm.nih.gov/40908723/). *Head Neck*. [Diagnostic / Biomarker]
Yan Y (2026). [PMID: 41699002](https://pubmed.ncbi.nlm.nih.gov/41699002/). *Sci Rep*. [Basic Science / Preclinical]
Wang Y (2026). [PMID: 42242002](https://pubmed.ncbi.nlm.nih.gov/42242002/). *J Craniomaxillofac Surg*. [Diagnostic / Biomarker]
Xia B (2026). [PMID: 41807827](https://pubmed.ncbi.nlm.nih.gov/41807827/). *Discov Oncol*. [Basic Science / Preclinical]
Li X (2026). [PMID: 41540537](https://pubmed.ncbi.nlm.nih.gov/41540537/). *Curr Cancer Drug Targets*. [Clinical Trial Publication]
Yuan Z (2026). [PMID: 41449832](https://pubmed.ncbi.nlm.nih.gov/41449832/). *Oral Dis*. [Epidemiology / Natural History]
Kakuguchi W (2026). [PMID: 41668712](https://pubmed.ncbi.nlm.nih.gov/41668712/). *Biomed Rep*. [Basic Science / Preclinical]
Kantibekovna SL (2026). [PMID: 41891963](https://pubmed.ncbi.nlm.nih.gov/41891963/). *Int J Oncol*. [Gene Therapy / Novel Therapeutics]
Kimura S (2026). [PMID: 41570726](https://pubmed.ncbi.nlm.nih.gov/41570726/). *Pathol Res Pract*. [Review / Meta-Analysis]